Donor telomere length and leukemia transplant outcomes
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at whether the length of telomeres (the protective caps at the ends of chromosomes) in donor blood cells affects recovery for people with acute leukemia who receive a stem cell transplant. It aims to see if a simple donor blood test can predict how well the transplant works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 5 years old.
- You have acute myeloid leukemia, acute lymphocytic leukemia, or mixed phenotype acute leukemia.
- You have already had your first stem cell transplant from a matched related, unrelated, or half-matched donor.
- Your leukemia went into complete remission after the transplant.
- Your donor had a blood sample taken before they received a medicine called G-CSF to mobilize stem cells.
- The transplant was successful, meaning your donor cells fully took over your bone marrow.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This study tests whether giving donor immune cells earlier or later after a stem cell transplant helps prevent relapse in people with tough-to-treat leukemia or MDS. Participants must be in remission one month after transplant.
This trial compares using your own stem cells versus a donor's stem cells for a transplant to treat T-lymphoblastic leukemia or lymphoma after you've reached first remission. The goal is to see which approach works better to keep the disease from coming back.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.